Logo

BMS Presents Interim Results of Zeposia (ozanimod) in P-III (True North) OLE Study for the Treatment of Active Ulcerative Colitis at ECCO 2022

Share this

BMS Presents Interim Results of Zeposia (ozanimod) in P-III (True North) OLE Study for the Treatment of Active Ulcerative Colitis at ECCO 2022

Shots:

  • The P-III (True North) OLE study evaluates Zeposia (0.92mg) vs PBO in 823 patients with UC with an inadequate response or intolerant to conventional therapy or a biologic agent
  • The results showed that the patients achieved clinical remission, clinical response, endoscopic improvement & corticosteroid-free remission was maintained @142wks. In an interim analysis @ 46/94/142wks., 45%/ 51%/45% were in clinical remission, 80%/84%/86% achieved clinical response, 64%/34%/14% patients completed a study
  • Patients achieved clinical remission & clinical response @46 & 94wk., (70% & 69%) & (95% & 98%), no new safety signals with Zeposia use in 1158 patients in the pooled population

 Ref: Businesswire | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions